Showing 20 of 67 recruiting trials for “Neuroblastoma”
APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors
TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma
👨⚕️ Qiang Zhao, Doctor, Tianjin Medical University Cancer Institute and Hospital📍 2 sites📅 Started Dec 2022View details ↗
Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
👨⚕️ Jaqueline Kraveka, DO, Medical University of South Carolina📍 23 sites📅 Started Sep 2022View details ↗
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RecruitingNCT07064746 ↗
Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma
👨⚕️ Guoqiang Shao, Dr, Nanjing First Hospital, Nanjing Medical University📍 1 site📅 Started Jul 2022View details ↗
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
👨⚕️ Chris DeRenzo, MD, St. Jude Children's Research Hospital📍 1 site📅 Started Jul 2022View details ↗
18F-mFBG LAFOV PET/CT Compared to 123I-mIBG Scintigraphy SPECT/CT for Evaluation of Children With Neuroblastoma
Quadruple Immunotherapy for Neuroblastoma
Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.
18F-DOPA II - PET Imaging Optimization
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
👨⚕️ Claudia Pasqualini, MD PhD, Gustave roussy, Paris, France📍 142 sites📅 Started Nov 2019View details ↗
RecruitingNCT04253015 ↗
A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta
RecruitingNCT04087902 ↗
Long-Term Longitudinal QoL in Patients Undergoing EEA
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
👨⚕️ George Hucks, MD, UNC Lineberger Comprehensive Cancer Center📍 2 sites📅 Started Feb 2019View details ↗
GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
👨⚕️ Ashish Gupta, MBBS, MPH, Masonic Cancer Center, University of Minnesota📍 1 site📅 Started Jun 2016View details ↗
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →